Management of Patients With Aggressive Nonmelanoma Skin Cancers
Search for other papers by Valencia D. Thomas in
Current site
Google Scholar
PubMed
Search for other papers by Michael K. Wong in
Current site
Google Scholar
PubMed
Search for other papers by Andrew J. Bishop in
Current site
Google Scholar
PubMed
Nonmelanoma skin cancers (NMSCs), which encompass a variety of cutaneous malignancies, are frequently managed with surgery, radiation therapy, cytotoxic chemotherapy, systemic immunotherapy, and active surveillance. In this tumor board–style forum, a panel of experts used several case studies as a basis to review these approaches and to describe existing clinical challenges. The current NCCN Guidelines for NMSC, which reflect the most up-to-date, evidence-based data relating to the evaluation and management of NMSCs, also provide key considerations and recommendations for the treatment of this patient population.
Disclosures: Dr. Thomas has disclosed serving as a scientific advisor for Merck & Co., Inc., Regeneron Pharmaceuticals, and sanofi-aventis U.S. Dr. Wong has disclosed serving as a scientific advisor for Bristol-Myers Squibb Company, Castle Biosciences, Inc., EMD Serono, Exicure, Inc., Merck & Co., Inc., Pfizer Inc., and Regeneron Pharmaceuticals, Inc. Dr. Bishop has disclosed having no relevant financial relationships.
© 2019-2024 National Comprehensive Cancer Network